Payment overview · 2025
General Payments
$2,794.43
174 reported records · 26 companies
Healthcare provider profile · identity verified
Robert T Ching, DO
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1770565707
Verified facts
What the public records show
CMS Open Payments records show Robert T Ching, DO received $2,794.43 in general payments during 2025 across 174 reported records.
Novo Nordisk Inc accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $525.34 | 18.8% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $404.59 | 14.5% | 25 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $274.53 | 9.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $251.40 | 9.0% | 32 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $210.80 | 7.5% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.60 | 7.1% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.54 | 5.1% | 12 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.22 | 4.0% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $90.33 | 3.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $89.51 | 3.2% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $82.68 | 3.0% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.24 | 2.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $58.32 | 2.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.51 | 1.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.96 | 1.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.40 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.43 | 1.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.75 | 0.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.17 | 0.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.12 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.20 | 0.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.19 | 0.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.92 | 0.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.77 | 0.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.14 | 0.5% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $7.77 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,794.43 | 174 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $352.09 | 16 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $262.82 | 17 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $239.72 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $224.29 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $210.80 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $202.52 | 28 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $179.52 | 25 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $173.25 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $167.79 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $143.54 | 12 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $111.22 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.07 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $99.88 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $90.33 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $89.51 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $76.26 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $72.24 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.54 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.81 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.43 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.96 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $7.77 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $7.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 87 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 295 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
295 | 56 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 30 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1127 | 405 |
| Amlodipine Besylate | Amlodipine Besylate | 504 | 184 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 127 |
| Losartan Potassium | Losartan Potassium | 392 | 151 |
| Tizanidine Hcl | Tizanidine Hcl | 374 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 353 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 124 |
| Valsartan | Valsartan | 339 | 119 |
| Omeprazole | Omeprazole | 298 | 91 |
| Ozempic | Semaglutide | 295 | 56 |
| Naproxen | Naproxen | 263 | 88 |
| Metformin Hcl | Metformin Hcl | 253 | 95 |
| Gabapentin | Gabapentin | 243 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 77 |
| Metformin Hcl Er | Metformin Hcl | 218 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 80 |
| Ibuprofen | Ibuprofen | 211 | 70 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 203 | 73 |
| Alendronate Sodium | Alendronate Sodium | 201 | 71 |
| Prednisone | Prednisone | 194 | 159 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 53 |
| Lisinopril | Lisinopril | 160 | 67 |
| Trazodone Hcl | Trazodone Hcl | 147 | 45 |
| Furosemide | Furosemide | 143 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 46 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 134 | 43 |
| Januvia | Sitagliptin Phosphate | 130 | 36 |
| Fenofibrate | Fenofibrate | 124 | 41 |
| Jardiance | Empagliflozin | 123 | 42 |
| Carvedilol | Carvedilol | 122 | 51 |
| Simvastatin | Simvastatin | 121 | 41 |
| Temazepam | Temazepam | 118 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 117 | 42 |
| Irbesartan | Irbesartan | 112 | 37 |
| Finasteride | Finasteride | 111 | 40 |
| Levofloxacin | Levofloxacin | 110 | 94 |
| Tramadol Hcl | Tramadol Hcl | 110 | 37 |
| Glimepiride | Glimepiride | 103 | 42 |
| Famotidine | Famotidine | 99 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 32 |
| Trulicity | Dulaglutide | 94 | 27 |
| Meloxicam | Meloxicam | 91 | 36 |
| Nifedipine Er | Nifedipine | 88 | 32 |
| Celecoxib | Celecoxib | 87 | 29 |
| Eliquis | Apixaban | 87 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 67 |
| Montelukast Sodium | Montelukast Sodium | 82 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 27 |
| Linzess | Linaclotide | 80 | 32 |
| Allopurinol | Allopurinol | 79 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 25 |
| Mounjaro | Tirzepatide | 74 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 28 |
| Potassium Chloride | Potassium Chloride | 67 | 22 |
| Buspirone Hcl | Buspirone Hcl | 65 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 29 |
| Meclizine Hcl | Meclizine Hcl | 60 | 33 |
| Ketoconazole | Ketoconazole | 59 | 30 |
| Sertraline Hcl | Sertraline Hcl | 57 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 18 |
| Xarelto | Rivaroxaban | 51 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 48 | 19 |
| Farxiga | Dapagliflozin Propanediol | 48 | 19 |
| Synthroid | Levothyroxine Sodium | 47 | 13 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Pregabalin | Pregabalin | 45 | 19 |
| Clonazepam | Clonazepam | 41 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 14 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 18 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Bumetanide | Bumetanide | 36 | 15 |
| Memantine Hcl | Memantine Hcl | 36 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 13 |
| Bupropion Xl | Bupropion Hcl | 33 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 14 |
| Glipizide | Glipizide | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | 11 |
| Spironolactone | Spironolactone | 31 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 29 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Baclofen | Baclofen | 26 | 11 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | 11 |
| Rybelsus | Semaglutide | 23 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | 12 |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Ramipril | Ramipril | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Prolia | Denosumab | 18 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,794.43 · 174 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, AREXVY, AUSTEDO XR, CAPLYTA, CAPVAXIVE, CONTRAVE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, INSPIRE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, M-M-R II, MOUNJARO, NURTEC ODT, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, OTEZLA, Ozempic, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, TOLMETIN SODIUM, TRELEGY ELLIPTA, TZIELD, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error